Fermentative production method of guanidinoacetic acid

Abstract

The present invention relates to a microorganism transformed with L-arginine:glycine amidotransferase, reduced malate synthase, and glyoxylate aminotransferase so as to be capable of producing guanidinoacetic acid (GAA), and a method for the fermentative production of GAA using such a microorganism. The present invention also relates to a method for the fermentative production of creatine.

Description

[Technical Field]

[0001] The present invention relates to a microorganism transformed to be capable of producing guanidinoacetic acid (GAA), and a method for the fermentative production of GAA using such a microorganism. The present invention also relates to a method for the fermentative production of creatine.

[0002] GAA is an organic compound used as an animal feed additive (US Patent Application Publication No. 2011257075). GAA is a natural precursor of creatine (e.g., Humm et al., Biochem. J. (1997) 322, 771-776). Therefore, adding GAA can optimize the supply of creatine to the body.

[0003] The present invention relates to a method for producing GAA by a fermentation process using industrial raw materials (e.g., ammonia, ammonium salts, and glucose or sugar-containing substrates) as starting materials. In biological systems, GAA and L-ornithine are produced from arginine and glycine as starting materials by the catalytic action of L-arginine:glycine amidinotransferase (AGAT; EC 2.1.4.1), which is the first step in creatine biosynthesis: [ka]

[0004] Guthmiller et al. (J Biol Chem. 1994 Jul 1;269(26):17556-60) characterized rat kidney AGAT by cloning and heterologously expressing the enzyme in E. coli. Muenchhoff et al. (FEBS Journal 277 (2010) 3844-3860) reported the first characterization of prokaryotic AGAT by cloning and heterologously expressing the enzyme in E. coli. Sosio et al. (Cell Chemical Biology 25, 540-549, May 17, 2018) elucidated the biosynthetic pathway of pseudouridimycin in Streptomyces sp. They describe the intermediate reaction of L-arginine with glycine, catalyzed by the L-arginine:glycine-amidinotransferase (AGAT), PumN, to produce GAA and L-ornithine.

[0005] Several approaches to increasing L-arginine production, one of the starting materials for GAA synthesis, in microorganisms, particularly bacteria, are known in the literature. An overview of metabolic engineering of Corynebacterium glutamicum (C. glutamicum) for L-arginine production is provided by Park et al. (NATURE COMMUNICATIONS | DOI: 10.1038 / ncomms5618). They proposed a stepwise, rational metabolic engineering approach based on random mutagenesis of already L-arginine-producing C. glutamicum strains, such as ATCC 21831 (Nakayama and Yoshida 1974; U.S. Patent No. 3,849,250), screening for L-arginine producers, and metabolic analysis of the entire system, gradually increasing L-arginine production through strain engineering steps. Yim et al. (J Ind Microbiol Biotechnol (2011) 38:1911-1920) were able to show that inactivating the gene encoding the central repressor protein ArgR, which controls the L-arginine biosynthetic pathway, by disrupting the argR gene on the C. glutamicum chromosome improved the arginine production of the strain. Ginesy et al. (Microbial Cell Factories (2015) 14:29) reported successful engineering of Escherichia coli for enhanced arginine production. Among other things, they proposed deleting the argR repressor gene.

[0006] reported a method using a genetically engineered strain in which the gene that suppresses the expression of the arginine biosynthetic operon argR was inactivated (US Patent Application Publication No. 20070031946). In particular, the deletion of argR, which controls the arginine operon, has been considered to be an important factor in arginine production.

[0007] Fan Wenchao has disclosed a method for producing creatine by fermenting non-pathogenic microorganisms, such as C. glutamicum (Chinese Patent Application Publication No. 106065411). This microorganism has the following biotransformation functions: conversion of glucose to L-glutamic acid; conversion of L-glutamic acid to N-acetyl-L-glutamic acid; conversion of N-acetyl-L-glutamic acid to N-acetyl-L-glutamic semialdehyde; conversion of N-acetyl-L-glutamic semialdehyde to N-acetyl-L-ornithine; conversion of N-acetyl-L-ornithine to L-ornithine; conversion of L-ornithine to L-citrulline; conversion of L-citrulline to argininosuccinic acid; conversion of argininosuccinic acid to L-arginine; conversion of L-arginine to guanidinoacetic acid; and finally conversion of guanidinoacetic acid to creatine. Fan Wenchao proposes that the microorganism overexpress one or more enzymes selected from the group consisting of N-acetylglutamate synthase, N-acetylornithine-δ-aminotransferase, N-acetylornithinase, ornithine-carbamoyltransferase, argininosuccinate synthetase, glycine amidinotransferase (EC:2.1.4.1), and guanidinoacetate-N-methyltransferase (EC:2.1.1.2). The microorganism preferably overexpresses glycine amidinotransferase (L-arginine:glycine amidinotransferase) and guanidinoacetate-N-methyltransferase.

[0008] As a second starting material for GAA biosynthesis, it may be desirable to increase the supply of glycine to improve GAA biosynthesis in microorganisms that naturally contain a homologous gene encoding a protein with the function of L-arginine:glycine amidinotransferase (AGAT) or in microorganisms that contain a heterologous gene encoding a protein with the function of L-arginine:glycine amidinotransferase (AGAT).

[0009] The so-called glyoxylate shunt pathway, which naturally occurs in microorganisms such as E. coli or C. glutamicum, is a side reaction of the tricarbonic acid (TCA) cycle (Krebs cycle) and involves the production of glyoxylate and succinate from isocitrate by isocitrate lyase, and the production of malate from glyoxylate and acetyl-CoA by malate synthase (Salusjarvi et al., Applied Microbiology and Biotechnology (2019) 103:2525-2535).

[0010] Glyoxylic acid may be used as a starting material to produce glycine in the presence of an amino donor, such as an amino acid, and glyoxylate transaminase.

[0011] In an attempt to improve glycolic acid production in C. glutamicum, Zahoor et al. (Journal of Biotechnology 192 (2014) 366-375) achieved, among other things, an increased supply of glyoxylic acid precursors by deleting the malate synthase gene aceB.

[0012] Glyoxylate transaminase catalyzes the transfer of an amino group from an amino acid to glyoxylate, the products of which are glycine and the corresponding α-keto acid.

[0013] Several glyoxylate aminotransferases are known, and their substrate specificities for amino donors differ (e.g., Kameya et al. FEBS Journal 277 (2010) 1876-1885; Liepman and Olsen, Plant Physiol. Vol. 131, 2003, 215-227; Sakuraba et al., JOURNAL OF BACTERIOLOGY, Aug. 2004, pp. 5513-5518; Takada and Noguchi, Biochem. J. (1985) 231, 157-163). Many of these glyoxylate aminotransferases can use different amino acids as amino donors, and are therefore often annotated with different EC numbers. However, all of these aminotransferases share a commonality: they use glyoxylate as the acceptor molecule or, in the case of the reverse reaction, glycine as the donor molecule.

[0014] Examples of proteins with glyoxylate aminotransferase function are: Glycine transaminase (EC 2.6.1.4) catalyzes the following reaction: L-glutamic acid + glyoxylic acid <=> α-ketoglutaric acid + glycine.

[0015] Glycine:oxaloacetate transaminase (EC 2.6.1.35) catalyzes the following reaction: L-aspartic acid + glyoxylic acid <=> oxaloacetic acid + glycine.

[0016] Alanine:glyoxylate transaminase (EC 2.6.1.44) catalyzes the following reaction: L-alanine + glyoxylic acid <=> pyruvic acid + glycine.

[0017] Serine:glyoxylate transaminase (EC 2.6.1.45) catalyzes the following reaction: L-serine + glyoxylic acid <=> 3-hydroxy-pyruvic acid + glycine.

[0018] Methionine:glyoxylate transaminase (EC 2.6.1.73) catalyzes the following reaction: L-Methionine + Glyoxylic Acid <=> 4-(Methylsulfanyl)-2-keto-butanoic acid + Glycine.

[0019] Aromatic amino acid:glyoxylate transaminase (EC 2.6.1.60) catalyzes the following reaction: Aromatic amino acid + glyoxylic acid <=> aromatic keto acid + glycine.

[0020] Kynurenine:glyoxylate transaminase (EC 2.6.1.63) catalyzes the following reaction: Kynurenine + glyoxylic acid <=> 4-(2-aminophenyl)-2,4-diketo-butanoic acid + glycine.

[0021] (S)-Ureido-glycine:glyoxylate transaminase (EC 2.6.1.112) catalyzes the following reaction: (S)-Ureido-glycine + glyoxylic acid <=> N-carbamoyl-2-keto-glycine + glycine.

[0022] The objective of the present invention is to provide a microorganism that has been transformed to be capable of producing guanidinoacetic acid (GAA), in particular a microorganism that has an improved ability to supply glycine as a starting material for GAA biosynthesis, and a method for the fermentative production of GAA using such a microorganism.

[0023] The object is achieved by a microorganism comprising at least one gene encoding a protein having the function of L-arginine:glycine amidinotransferase, wherein the activity of the protein having the function of malate synthase is reduced compared to the respective activity in a wild-type microorganism.

[0024] The activity of a protein having the functionality of malate synthase can be reduced by mutating the protein to a protein having lower enzymatic activity than the wild-type protein, by attenuating the expression of the gene encoding the enzyme having the functionality of malate synthase compared to the expression of the respective gene in a wild-type microorganism, by reducing the efficiency of translation, for example, by changing the ATG start codon to GTG, by introducing a secondary structure in the 5' untranslated region of the mRNA, or by attenuating codon usage, or by deleting the gene encoding the enzyme having the functionality of malate synthase.

[0025] Preferably, in the microorganism according to the present invention, the expression of the gene encoding the protein having the function of malate synthase is attenuated compared to the expression of the respective gene in a wild-type microorganism, or the gene encoding the protein having the function of malate synthase is deleted.

[0026] In a further embodiment of the invention, the microorganism of the invention further comprises an increased activity of an enzyme having the function of glyoxylate aminotransferase compared to the respective enzymatic activity in a wild-type microorganism.

[0027] The microorganism according to the invention preferably comprises at least one gene encoding a protein with the enzymatic activity of glyoxylate aminotransferase.

[0028] In the microorganism of the present invention, at least one gene encoding a protein having the enzymatic activity of glyoxylate aminotransferase is homologous or heterologous.

[0029] In a further embodiment of the invention, at least one gene encoding a protein having the enzymatic activity of glyoxylate aminotransferase is overexpressed in the microorganism of the invention.

[0030] Preferably, the microorganism of the present invention has an improved ability to produce L-arginine compared to the ability of a wild-type microorganism.

[0031] In the context of the present invention, a microorganism with improved L-arginine production ability refers to a microorganism that produces L-arginine in excess of its own requirements. Examples of such L-arginine-producing microorganisms include C. glutamicum ATCC 21831, or those disclosed by Park et al. (NATURE COMMUNICATIONS | DOI: 10.1038 / ncomms5618) or Ginesy et al. (Microbial Cell Factories (2015) 14:29).

[0032] In a particular embodiment of the present invention, the microorganism has an increased activity of an enzyme having the function of carbamoyl phosphate synthase (EC 6.3.4.16) compared to the respective enzyme activity in a wild-type microorganism.

[0033] In the microorganism according to the present invention, the activity of an enzyme having the function of argininosuccinate lyase (EC.4.3.2.1) may be increased compared to the respective enzymatic activity in a wild-type microorganism.

[0034] Furthermore, in the microorganism according to the present invention, the activity of an enzyme having the function of ornithine carbamoyltransferase (EC 2.1.3.3) is increased compared to the respective enzyme activity in a wild-type microorganism.

[0035] In the microorganism according to the invention, the activity of an enzyme having the function of argininosuccinate synthetase (EC 6.3.4.5) may also be increased compared to the respective enzymatic activity in a wild-type microorganism.

[0036] Increasing the enzyme activity in a microorganism can be achieved, for example, by mutating the corresponding endogenous gene. Another strategy for increasing enzyme activity may be to stabilize the mRNA encoding the enzyme. In addition, increasing the activity of the enzyme can also be achieved by overexpressing the gene encoding the respective enzyme.

[0037] Furthermore, the microorganism according to the present invention preferably comprises at least one or more overexpressed genes selected from the group consisting of a gene encoding a protein having the function of ornithine carbamoyltransferase (EC 2.1.3.3) (e.g., argF / argF2 / argI), a gene encoding a protein having the function of argininosuccinate synthetase (EC 6.3.4.5) (e.g., argG), and a gene encoding a protein having the function of argininosuccinate lyase (EC 4.3.2.1) (e.g., argH).

[0038] Furthermore, the arginine operon (argCJBDFR) may be overexpressed in the microorganism according to the present invention.

[0039] Alternatively, in the microorganism according to the present invention, the argR gene encoding the arginine-responsive repressor protein ArgR may be attenuated or deleted.

[0040] In a further embodiment of the invention, and optionally in addition to the above modifications, at least one or more genes encoding enzymes of the L-arginine biosynthetic pathway, including gdh, argJ, argB, argC and / or argD, which encode glutamate dehydrogenase, ornithine acetyltransferase, acetylglutamate kinase, acetylglutamylphosphate reductase and acetylornithine aminotransferase, respectively, are overexpressed in the microorganism according to the invention.

[0041] Table 1 shows the different names of the enzymes involved in or contributing to arginine biosynthesis in different species, namely, E. coli, C. glutamicum and P. putida.

[0042] [Table 1-1] [Table 1-2]

[0043] Overexpression of a gene is generally achieved by increasing the copy number of the gene, and / or operably linking the gene to a strong promoter, and / or strengthening the ribosome binding site, and / or optimizing the codon usage of the start codon or the entire gene, or a combination including any or all of the above methods.

[0044] In a further embodiment of the microorganism of the invention, the gene encoding a protein with the function of L-arginine:glycine amidinotransferase is heterologous.

[0045] A heterologous gene means that the gene has been inserted into a host organism that does not naturally possess this gene. The insertion of a heterologous gene into a host is achieved through recombinant DNA technology. Microorganisms that have undergone recombinant DNA technology are called transgenic, genetically modified, or recombinant.

[0046] Heterologous protein means a protein that does not naturally occur in the microorganism.

[0047] By homologous gene or endogenous gene is meant that the gene or the nucleotide sequence of the gene, including its function itself, occurs naturally in the microorganism or is "native" to the microorganism.

[0048] A homologous protein or native protein means a protein that occurs naturally in a microorganism.

[0049] Proteins with the function of L-arginine:glycine amidinotransferase (AGAT) belong to the amidinotransferase family. The amidinotransferase family includes glycine (EC:2.1.4.1) and inosamine (EC:2.1.4.2) amidinotransferases, enzymes involved in the biosynthesis of creatine and streptomycin, respectively. This family also includes arginine deiminase (EC:3.5.3.6). These enzymes catalyze the reaction: arginine + HO <=> citrulline + NH3. This family also includes the Streptococcus antitumor glycoprotein. Enzymes or proteins with L-arginine:glycine-amidinotransferase (AGAT) activity have also been described that have a conserved domain, Amidinotransf (PF02274), belonging to the PFAM family (Marchler-Bauer A et al., Mol Gen Genet 1991;231:113-123 (PUBMED:1661369 EPMC:1661369); D'Hooghe I et al., J Bacteriol 1997;179:7403-7409 (PUBMED:9393705 EPMC:9393705); Kanaoka M et al., Jpn J Cancer Res 1987;78:1409-1414 (PUBMED:3123442 EPMC:3123442) (Marchler-Bauer A et al., (2017), “CDD / SPARCLE: functional classification of proteins via subfamily domain architectures.”, Nucleic Acids Res. 45(D1):D 200-D203.).

[0050] In the microorganism of the present invention, a gene encoding a protein having the function of L-arginine:glycine amidinotransferase may also be overexpressed. Overexpression of the gene is generally achieved by increasing the copy number of the gene, and / or operably linking the gene to a strong promoter, and / or strengthening the ribosome binding site, and / or optimizing the codon usage of the start codon or the entire gene, or a combination including any of the above methods.

[0051] A protein having the function of L-arginine:glycine amidinotransferase in a microorganism of the invention may comprise an amino acid sequence that is at least 80% homologous, preferably at least 90% homologous, to the amino acid sequence according to SEQ ID NO: 11. In a further embodiment of the invention, the amino acid sequence of the L-arginine:glycine amidinotransferase is the same as the amino acid sequence according to SEQ ID NO: 11.

[0052] In a particular embodiment of the invention, the protein having the enzymatic activity of glyoxylate aminotransferase in a microorganism according to the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence according to SEQ ID NO:2, to the amino acid sequence according to SEQ ID NO:5 or to the amino acid sequence according to SEQ ID NO:8.

[0053] The microorganism of the present invention may belong to the genus Corynebacterium, preferably Corynebacterium glutamicum (C. glutamicum), or the genus Enterobacteriaceae, preferably Escherichia coli (E. coli), or the genus Pseudomonas, preferably Pseudomonas putida (P. putida).

[0054] In a microorganism, in particular a microorganism of the invention, an increased enzymatic activity of a protein compared to the respective activity in a wild-type microorganism can be achieved, for example, by a mutation in the protein, in particular a mutation that confers feedback resistance to the protein, for example to the product of an enzyme-catalyzed reaction, or by increasing the expression of a gene encoding a protein with enzymatic activity compared to the expression of the respective gene in a wild-type microorganism.

[0055] Increased expression or overexpression of genes in microorganisms, particularly the microorganisms of the present invention, compared to their respective activity in wild-type microorganisms can be achieved by increasing the copy number of the gene and / or enhancing regulatory factors, for example, by functionally linking the gene to a strong promoter and / or strengthening the ribosome binding site, and / or optimizing the codon usage of the start codon or the entire gene. Enhancement of such regulatory factors that positively affect gene expression can be achieved, for example, by modifying the promoter sequence upstream of the structural gene to increase promoter efficiency, or by completely replacing the aforementioned promoter with a more effective or so-called strong promoter. The promoter is located upstream of the gene. A promoter is a DNA sequence consisting of approximately 40 to 50 base pairs that constitutes a binding site for RNA polymerase holoenzyme and a transcription initiation site, thereby influencing the strength of expression of the controlled polynucleotide or gene. In general, it is possible to achieve overexpression or increased expression of a gene in bacteria by selecting a strong promoter, for example, by replacing the original promoter with a strong, native promoter (originally assigned to another gene), or by modifying specific regions of a given native promoter (for example, its so-called -10 and -35 regions) toward a consensus sequence, as taught, for example, by M. Patek et al. (Microbial Biotechnology 6 (2013), 103-117) for C. glutamicum. An example of a "strong" promoter is the superoxide dismutase (sod) promoter ("Psod"; Z. Wang et al., Eng. Life Sci. 2015, 15, 73-82). "Operatively linked" is understood to mean that the promoter is sequentially arranged with the gene, thereby resulting in transcription of the gene.

[0056] The genetic code is degenerate, meaning that an amino acid may be coded for by many different triplets. The term codon usage refers to the observation that an organism does not usually use all possible codons corresponding to an amino acid with equal frequency. Instead, an organism usually exhibits a preference for certain codons, and these codons are found more frequently in the coding sequences of the organism's transcribed genes. If a gene foreign to a future host, i.e., from a different species, is to be expressed in the future host organism, the coding sequence of said gene should be adjusted to the codon usage of said future host organism (i.e., codon usage optimization).

[0057] The above-mentioned problems are further solved by a method for the fermentative production of guanidinoacetic acid (GAA), comprising the steps of: a) culturing a microorganism according to the invention as defined above in a suitable medium under suitable conditions; and b) accumulating GAA in the medium to produce a GAA-containing fermentation broth.

[0058] The method according to the invention may further comprise the step of isolating GAA from the fermentation broth.

[0059] The method according to the present invention may further comprise the step of drying and / or granulating the fermentation broth containing GAA.

[0060] The present invention further relates to a microorganism as defined above, further comprising a gene encoding an enzyme having the activity of guanidinoacetate-N-methyltransferase (EC:2.1.1.2). Preferably, the gene encoding the enzyme having the activity of guanidinoacetate-N-methyltransferase is overexpressed.

[0061] The present invention also relates to a method for the fermentative production of creatine, comprising the steps of: a) culturing a microorganism according to the present invention, which comprises a gene encoding an enzyme having the activity of guanidinoacetate-N-methyltransferase, in a suitable medium under suitable conditions; and b) accumulating creatine in the medium to produce a creatine-containing fermentation broth.

[0062] Preferably, the method further comprises isolating creatine from the creatine-containing fermentation broth. Creatine can be extracted from the fermentation broth by isoelectric focusing and / or ion exchange. Alternatively, creatine can be further purified by recrystallization in water.

[0063] Example A) Materials and Methods chemicals Kanamycin solution from Streptomyces kanamyceticus was purchased from Sigma Aldrich (St. Louis, USA, Cat. no. K0254). IPTG (isopropyl-β-thiogalactopyranoside) was purchased from Carl-Roth (Karlsruhe, Germany, Cat. no. 2316.4). Unless otherwise noted, all other chemicals were purchased analytically pure from Merck (Darmstadt, Germany), Sigma Aldrich (St. Louis, USA), or Carl-Roth (Karlsruhe, Germany).

[0064] Culture for cell growth Unless otherwise noted, culture / incubation procedures are as follows: a. E. coli strains were grown in liquid medium using LB broth (MILLER) from Merck (Darmstadt, Germany; Cat. no. 110285). Liquid cultures (10 ml of liquid medium per three baffled 100 ml Erlenmeyer flasks) were incubated at 30°C and 200 rpm in an Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland).

[0065] b. E. coli strains were grown on agar plates using LB agar (MILLER) from Merck (Darmstadt, Germany, Cat. no. 110283). The agar plates were incubated at 30°C in an INCU-Line® mini-incubator from VWR (Radnor, USA).

[0066] C. glutamicum strains were cultivated in liquid medium using brain heart infusion medium (BHI) from c. Merck (Darmstadt, Germany, Cat. no. 110493). Liquid cultures (10 ml of liquid medium per three baffled 100 ml Erlenmeyer flasks) were incubated at 30°C and 200 rpm in an Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland).

[0067] d. C. glutamicum strains were grown on agar plates using Brain Heart Agar (BHI agar) from Merck (Darmstadt, Germany, Cat. no. 113825). The agar plates were incubated at 30°C in a Heraeus Instruments Kelvitron® temperature-controlled incubator (Hanau, Germany).

[0068] e. To culture C. glutamicum after electroporation, BHI agar (Merck, Darmstadt, Germany, Cat. no. 113825) was supplemented with 134 g / L sorbitol (Carl Roth GmbH + Co. KG, Karlsruhe, Germany), 2.5 g / L yeast extract (Oxoid / ThermoFisher Scientific, Waltham, USA, Cat. no. LP0021), and 25 mg / L kanamycin. Agar plates were incubated at 30°C in a Heraeus Instruments Kelvitron® temperature-controlled incubator (Hanau, Germany).

[0069] Measurement of the optical density of bacterial suspensions a The optical density of bacterial suspensions in shake flask cultures was measured at 600 nm (OD600) using a BioPhotometer from Eppendorf AG (Hamburg, Germany).

[0070] b. Optical density at 660 nm (OD660) of bacterial suspensions produced in Wouter Duetz (WDS) microfermentation systems (24-well plates) was measured using a GENios™ plate reader from Tecan Group AG (Maennedorf, Switzerland).

[0071] Centrifugation a. A maximum volume of 2 ml of the bacterial suspension was placed into 1.5 ml or 2 ml reaction tubes (e.g., Eppendorf Tubes® 3810X) and centrifuged (5 min, 13,000 rpm) using an Eppendorf 5417R benchtop centrifuge.

[0072] b. A maximum volume of 50 ml of the bacterial suspension was placed into a 15 ml or 50 ml centrifuge tube (e.g., a Falcon™ 50 ml conical centrifuge tube) and centrifuged at 4,000 rpm for 10 minutes in an Eppendorf 5810R benchtop centrifuge.

[0073] DNA isolation Plasmid DNA was isolated from E. coli cells using the QIAprep Spin Miniprep Kit from Qiagen (Hilden, Germany, Cat. No. 27106) according to the manufacturer's instructions.

[0074] polymerase chain reaction (PCR) PCR with a proofreading (high-fidelity) polymerase was used to amplify desired segments of DNA for Sanger sequencing or DNA assembly. A non-proofreading polymerase kit was used to determine the presence or absence of desired DNA fragments directly from E. coli or C. glutamicum colonies.

[0075] a. Selected DNA regions were amplified using the Phusion® High-Fidelity DNA Polymerase Kit (Phusion kit) from New England BioLabs Inc. (Ipswich, USA, Cat. No. M0530) according to the manufacturer's instructions (see Table 2).

[0076] [Table 2]

[0077] b. The desired DNA segment was amplified and its presence confirmed using the Taq PCR Core Kit (Taq kit) from Qiagen (Hilden, Germany, Cat. No. 201203). The kit was used according to the manufacturer's instructions (see Table 3).

[0078] [Table 3]

[0079] c. SapphireAmp® Fast PCR Master Mix (Sapphire Mix) from Takara Bio Inc. (Takara Bio Europe SAS, Saint-Germain-en-Laye, France, Cat. No. RR350A / B) was used instead to confirm the presence of the desired DNA segment in cells taken from E. coli or C. glutamicum colonies according to the manufacturer's instructions (see Table 4).

[0080] [Table 4]

[0081] d. All oligonucleotide primers were synthesized by Eurofins Genomics GmbH (Ebersberg, Germany) using the phosphoramidite method described by McBride and Caruthers (1983).

[0082] e. An appropriate dilution of isolated plasmid DNA, total DNA isolated from a liquid culture, or total DNA contained in a bacterial colony was used as the PCR template (colony PCR). For the colony PCR described above, the template was prepared by harvesting cellular material from a colony on an agar plate with a toothpick and placing the cellular material directly into a PCR reaction tube. The cellular material was then microwaved at 800W for 10 seconds in a Mikrowave & Grill type microwave oven (SEVERIN Elektrogeraete GmbH, Sundern, Germany), and PCR reagents were added to the template in the PCR reaction tube.

[0083] f. All PCR reactions were performed in a Mastercycler or Mastercycler nexus gradient type PCR cycler from Eppendorf AG (Hamburg, Germany).

[0084] Restriction enzyme digestion of DNA For restriction enzyme digestion, "FastDigest Restriction Endonuclease (FD)" (ThermoFisher Scientific, Waltham, USA) or restriction endonucleases from New England BioLabs Inc. (Ipswich, USA) were used. The reactions were performed according to the manufacturer's instructions.

[0085] Measurement of DNA fragment size a, The size of small DNA fragments (<1000 bps) was routinely determined by automated capillary electrophoresis using QIAxcel from Qiagen (Hilden, Germany).

[0086] b. If DNA fragments needed to be isolated or were larger than 1000 bps, the DNA was separated by TAE agarose gel electrophoresis and stained with GelRed® nucleic acid gel stain (Biotium, Inc., Fremont, Canada). The stained DNA was visualized at 302 nm.

[0087] Purification of PCR amplicons and restriction fragments PCR amplification products and restriction fragments were cleaned up using the QIAquick PCR Purification Kit from Qiagen (Hilden, Germany; Cat. No. 28106) according to the manufacturer's instructions. DNA was eluted in 30 μl of 10 mM Tris·HCl (pH 8.5).

[0088] Measurement of DNA concentration DNA concentrations were measured using a NanoDrop spectrophotometer ND-1000 from PEQLAB Biotechnologie GmbH (VWR brand, Erlangen, Germany, since 2015).

[0089] Assembly cloning Plasmid vectors were assembled using the "NEBuilder HiFi DNA Assembly Cloning Kit" purchased from New England BioLabs Inc. (Ipswich, USA, Cat. No. E5520). The reaction mixture containing the linearized vector and at least one DNA insert was incubated at 50°C for 60 minutes. 0.5 μl of the assembly mixture was used for each transformation experiment.

[0090] Chemical transformation of E. coli For plasmid cloning, chemically competent "NEB® Stable Competent E. coli (High Efficiency)" (New England BioLabs Inc., Ipswich, USA, Cat. No. C3040) was transformed according to the manufacturer's protocol. Successfully transformed cells were selected on LB agar medium supplemented with 25 mg / L kanamycin.

[0091] Transformation of C. glutamicum Transformation of C. glutamicum with plasmid DNA was performed by electroporation using a "Gene Pulser Xcell" (Bio-Rad Laboratories GmbH, Feldkirchen, Germany) as described by Ruan et al. (2015). Electroporation was performed in a 1 mm electroporation cuvette (Bio-Rad Laboratories GmbH, Feldkirchen, Germany) at 1.8 kV and a fixed time constant set at 5 ms. Transformed cells were selected on BHI agar containing 134 g / L sorbitol, 2.5 g / L yeast extract, and 25 mg / L kanamycin.

[0092] Nucleotide sequence determination The nucleotide sequences of the DNA molecules were determined by cycle sequencing using the dideoxy chain termination method of Sanger et al. (Proceedings of the National Academy of Sciences USA 74, 5463-5467, 1977) at Eurofins Genomics GmbH (Ebersberg, Germany). Sequence visualization and evaluation were performed using Clonemanager Professional 9 software from Scientific & Educational Software (Denver, USA).

[0093] Glycerol stocks of E. coli and C. glutamicum strains Glycerol stocks were prepared for long-term storage of E. coli and C. glutamicum. Selected E. coli strains were cultured in 10 ml of LB medium supplemented with 2 g / L glucose. Selected C. glutamicum strains were cultured in 10 ml of double-concentrated BHI medium supplemented with 2 g / L glucose. The medium for culturing plasmid-containing E. coli and C. glutamicum strains was supplemented with 25 mg / L kanamycin. The medium was placed in a 100 ml Erlenmeyer flask with three baffles. A loop of cells from a colony was inoculated into the medium. The culture was then incubated at 30°C and 200 rpm for 18 hours. After the incubation period, 1.2 ml of 85% (v / v) sterile glycerol was added to the culture. The resulting glycerol-containing cell suspension was then divided into 2 ml aliquots and stored at -80°C.

[0094] GAA production in milliliter-scale cultures The strains were evaluated for GAA production using the milliliter-scale culture system described by Duetz (2007) in 24-deep-well microplates (24-well WDS plates) from EnzyScreen BV (Heemstede, Netherlands, Cat. no. CR1424) filled with 2.5 ml of medium per well.

[0095] The strains were pre-cultured in 10 ml of seed medium (SM). The medium was placed in three baffled 100 ml Erlenmeyer flasks. This was inoculated with 100 μl of glycerol stock culture and incubated at 30°C and 200 rpm for 24 hours. The composition of seed medium (SM) is shown in Table 5.

[0096] [Table 5]

[0097] After the aforementioned incubation period, the optical density (OD) of the pre-culture was measured. An amount of pre-culture was sampled to inoculate 2.5 ml of production medium (PM) to an OD of 0.1, centrifuged (8000 g for 1 minute), and the supernatant was discarded. The cells were then resuspended in 100 μl of production medium.

[0098] The main culture was initiated by inoculating 100 μl of the resuspended cells from the preculture into each well of a 24-well WDS plate containing 2.4 ml of production medium (PM). The composition of the production medium (PM) is shown in Table 6.

[0099] [Table 6]

[0100] The main culture was incubated in an Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) at 30°C and 300 rpm for 72 hours until glucose was completely consumed. The glucose concentration in the suspension was analyzed using a OneTouch Vita® blood glucose meter from LifeScan (Johnson & Johnson Medical GmbH, Neuss, Germany).

[0101] After incubation, the culture suspension was transferred to a deep-well microplate. A portion of the culture suspension was appropriately diluted to measure OD660. Another portion of the culture was centrifuged, and the GAA concentration in the supernatant was analyzed as described below.

[0102] Determination of L-arginine and glycine contents in yeast peptone FM902 Yeast extract FM902 (Angel Yeast Co., Ltd., Hubei, PRChina) contains various peptides and amino acids, so its L-arginine and glycine contents were measured as follows.

[0103] To measure free amino acids, a sample was prepared by dissolving 1 g of yeast extract in 20 ml of water. Water was added to this solution to make the total volume 25 ml, and after thorough mixing, the solution was filtered using a 0.2 μM nylon syringe filter.

[0104] For the determination of total amino acids (free amino acids + peptide-bound amino acids), samples were prepared by dissolving 1 g of yeast extract in 10 ml of 6 M HCl and incubating at 110°C for 24 hours. Water was then added to bring the total volume to 25 ml. The solution was mixed thoroughly and filtered using a 0.2 μM nylon syringe filter.

[0105] The concentrations of L-arginine and glycine in the samples were determined by ion exchange chromatography using a SYKAM S433 amino acid analyzer from SYKAM Vertriebs GmbH (Fuerstenfeldbruck, Germany). The column consisted of a spherical polystyrene-based cation exchanger (Peek LCA N04 / Na, dimensions 150 × 4.6 mm) from SYKAM. Depending on the L-amino acid, separation was performed by isocratic elution with a mixture of buffers A and B, or by gradient elution with the aforementioned buffers. Buffer A consisted of an aqueous solution containing 263 g trisodium citrate, 120 g citric acid, 1100 ml methanol, 100 ml 37% HCl, and 2 ml octanoic acid in a 20 L solution (final pH 3.5). Buffer B consisted of an aqueous solution containing 392 g trisodium citrate, 100 g boric acid, and 2 ml octanoic acid in a 20 L solution (final pH 10.2). Free amino acids were stained with ninhydrin by post-column derivatization and detected photometrically at 570 nm.

[0106] Table 7 shows the free and total L-arginine and glycine contents measured in yeast extract FM902 (Angel Yeast Co., LTD, Hubei, PRChina) and the resulting amounts in the production medium (PM).

[0107] [Table 7]

[0108] Quantification of GAA The samples were analyzed using an Agilent analytical system consisting of an HPLC "Infinity 1260" and a mass spectrometer "Triple Quad 6420" (Agilent Technologies Inc., Santa Clara, USA). Chromatographic separation was performed on an Atlantis HILIC silica column, 4.6 × 250 mm, 5 μm (Waters Corporation, Milford, USA) at 35 °C. Mobile phase A was water containing 10 mM ammonium formate and 0.2% formic acid. Mobile phase B was a mixture of 90% acetonitrile and 10% water, to which 10 mM ammonium formate was added. The HPLC system started at 100% B and then ran a linear gradient to 66% B at a constant flow rate of 0.6 mL / min over 22 min. The mass spectrometer was operated in ESI positive ionization mode. To detect GAA, the m / z values ​​were monitored using the MRM fragment [M+H]+118-76. The limit of quantitation (LOQ) of GAA was fixed at 7 ppm.

[0109] B) Experimental results Example 1: Cloning of the gene GGT1 encoding glyoxylate aminotransferase from Arabidopsis thaliana The Arabidopsis gene GGT1 (Genbank accession number NM_102180, SEQ ID NO:1) encodes glutamate:glyoxylate aminotransferase (Genbank accession number NP_564192, SEQ ID NO:2). This protein was found to catalyze the reactions glyoxylate + L-alanine = glycine + pyruvate (EC 2.6.1.44), 2-oxoglutarate + L-alanine = L-glutamate + pyruvate (EC 2.6.1.2), and 2-oxoglutarate + glycine = glyoxylate + L-glutamate (EC 2.6.1.4; Liepman AH, Olsen LJ., Plant Physiol. 2003 Jan;131(1):215-27. doi: 10.1104 / pp.011460).

[0110] The amino acid sequence of the GGT1 protein was translated into a DNA sequence optimized for C. glutamicum codon usage using the software tool "Codon Optimization Tool" (Integrated DNA Technologies Inc., Coralville, Iowa, USA). A Shine-Dalgarno sequence (AGGAAAGGAGAGGATTG; Shi, 2018) was added directly upstream of the open reading frame, and the ends of the resulting sequence were extended with a motif for subsequent subcloning. The resulting DNA sequence, AtGGT1_opt_RBS (SEQ ID NO:3), was ordered for gene synthesis from Eurofins Genomics GmbH (Ebersberg, Germany) and provided as part of a cloning plasmid (designated pEX-A258-AtGGT1_opt_RBS) that confers resistance to ampicillin.

[0111] Example 2: Cloning of the Arabidopsis GGT2 gene encoding glyoxylate aminotransferase The Arabidopsis gene AOAT2 (synonym: GGT2) (Genbank accession number NM_001036185, SEQ ID NO: 4) encodes alanine-2-oxoglutarate aminotransferase 2 (Genbank accession number NP_001031262, SEQ ID NO: 5). This protein was found to catalyze the reactions glyoxylate + L-alanine = glycine + pyruvate (EC 2.6.1.44), 2-oxoglutarate + L-alanine = L-glutamate + pyruvate (EC 2.6.1.2), and 2-oxoglutarate + glycine = glyoxylate + L-glutamate (EC 2.6.1.4; Liepman AH, Olsen LJ., Plant Physiol. 2003 Jan;131(1):215-27. doi: 10.1104 / pp.011460).

[0112] The amino acid sequence of the GGT2 protein was translated into a DNA sequence optimized for C. glutamicum codon usage using the software tool "Codon Optimization Tool" (Integrated DNA Technologies Inc., Coralville, Iowa, USA). A Shine-Dalgarno sequence (AGGAAAGGAGAGGATTG; Shi, 2018) was added directly upstream of the open reading frame, and the ends of the resulting sequence were extended with motifs for subsequent subcloning. The resulting DNA sequence, AtGGT2_opt_RBS (SEQ ID NO: 6), was ordered for gene synthesis from Eurofins Genomics GmbH (Ebersberg, Germany) and provided as part of a cloning plasmid (designated pEX-A258-AtGGT2_opt_RBS) that confers resistance to ampicillin.

[0113] Example 3: Cloning of the gene agt encoding glyoxylate aminotransferase from the hyperthermophilic archaeon Thermococcus litoralis The hyperthermophilic archaeal gene agt (Genbank accession number AB033996, SEQ ID NO:7) encodes alanine:glyoxylate aminotransferase (Genbank accession number BAB40321, SEQ ID NO:8). This protein was found to catalyze the reactions glyoxylate + L-alanine = glycine + pyruvate (EC 2.6.1.44) and glyoxylate + L-serine = glycine + 3-hydroxypyruvate (EC 2.6.1.45; Sakuraba, 2004).

[0114] The amino acid sequence of the Agt protein was translated into a DNA sequence optimized for C. glutamicum codon usage using the software tool "Codon Optimization Tool" (Integrated DNA Technologies Inc., Coralville, Iowa, USA). A Shine-Dalgarno sequence (AGGAAAGGAGAGGATTG; Shi, 2018) was added directly upstream of the open reading frame, and the end of the resulting sequence was extended with a motif for subsequent subcloning. The resulting DNA sequence (SEQ ID NO:9) was ordered for gene synthesis from Eurofins Genomics GmbH (Ebersberg, Germany) and provided as part of a cloning plasmid (designated pEX-A258-AGT_Tl_opt_RBS) that confers resistance to ampicillin.

[0115] Example 4: Cloning of the gene AGAT_Mp encoding L-arginine:glycine amidinotransferase (AGAT, EC2.1.4.1) from Moorea producens Moorea producens is a filamentous cyanobacterium. The genome of Moorea producens strain PAL-8-15-08-1 was published by Leao et al. (Leao T, Castelao G, Korobeynikov A, Monroe EA, Podell S, Glukhov E, Allen EE, Gerwick WH, Gerwick L, Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3198-3203. doi: 10.1073 / pnas.1618556114; GenBank accession number CP017599.1). It contains an open reading frame putatively encoding L-arginine:glycine amidinotransferase (AGAT, EC2.1.4.1; locus_tag BJP34_00300, shown in SEQ ID NO:10). SEQ ID NO:11 shows the derived amino acid sequence (Genbank accession number WP_070390602).

[0116] Using the software tool "Codon Optimization Tool" (Geneart / ThermoFisher Scientific, Waltham, USA), this amino acid sequence was translated into a DNA sequence optimized for C. glutamicum codon usage. The ends were extended with sequences for assembly cloning, and a Shine-Dalgarno sequence (AGGA) was added 5 base pairs upstream of the open reading frame. The resulting DNA sequence (SEQ ID NO: 12) was ordered for gene synthesis from Invitrogen / Geneart (ThermoFisher Scientific, Waltham, USA), and it was provided as part of the cloning plasmid (designated pMA-T_AGAT_Mp).

[0117] Example 5: Cloning of AGAT_Mp into expression plasmid pEC-XK99E The E. coli-C. glutamicum shuttle plasmid pEC-XK99E (Genbank accession number AY219682) was digested with the restriction endonuclease SmaI. Terminal phosphates were removed using "FastAP Thermosensitive Alkaline Phosphatase" (Thermo Fisher Scientific, Waltham, USA). The DNA was then purified using "QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).

[0118] The cloning plasmid pMA-T_AGAT_Mp was digested with MluI and AatII, and the resulting fragment was blunted using the "Fast DNA End Repair Kit" (Thermo Fisher Scientific, Waltham, USA). They were separated by agarose gel electrophoresis (0.8% agarose in TAE buffer), and the band corresponding to "AGAT_Mp" (1174 bp) was excised. The DNA was purified using the "QIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany).

[0119] The AGAT_Mp fragment and linearized pEC-XK99E were ligated using "Ready-To-Go T4 DNA ligase" (GE Healthcare Europe GmbH, Freiburg, Germany). The ligation product was transformed into "NEB Stable Competent E. coli (High Efficiency)" (New England Biolabs, Ipswich, USA), and cells were grown on LB agar medium containing 25 mg / L kanamycin. Correct clones were identified by restriction enzyme digestion and DNA sequencing. The resulting plasmid was designated pEC-XK99E_AGAT_Mp.

[0120] Example 6: Cloning of the glyoxylate aminotransferase gene into the expression plasmid pEC-XK99E_AGAT_Mp Plasmid pEC-XK99E_AGAT_Mp was digested with the restriction endonuclease BamHI, and the terminal phosphate was removed using FastAP Thermosensitive Alkaline Phosphatase (Thermo Fisher Scientific, Waltham, USA). The digested DNA was then purified using a QIAquick Gel Extraction Kit (Qiagen GmbH, Hilden, Germany).

[0121] The cloning plasmids pEX-A258-AtGGT1_opt_RBS, pEX-A258-AtGGT2_opt_RBS, and pEX-A258-AGT_Tl_opt_RBS were digested with BamHI and BsaI, respectively, and the digested plasmids were purified using a "QIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany).

[0122] The digested pEC-XK99E_AGAT_Mp was ligated with each digested cloning plasmid using "Ready-To-Go T4 DNA ligase" (GE Healthcare Europe GmbH, Freiburg, Germany). The ligation product was transformed into "NEB Stable Competent E. coli (High Efficiency)" (New England Biolabs, Ipswich, USA), and the cells were grown on LB agar medium containing 25 mg / L kanamycin. Correct clones were identified by restriction enzyme digestion and DNA sequencing.

[0123] The resulting plasmids are shown in Table 8. They provide the AGAT_Mp gene and the respective glyoxylate aminotransferase in an operon-like structure under the control of the strong IPTG-inducible trc-promoter.

[0124] [Table 8]

[0125] Example 7: Chromosomal insertion of the sod promoter upstream of the carAB operon in ATCC13032 To improve L-arginine production, a strong sod promoter was inserted into the genome of ATCC13032 upstream of the carAB operon. Therefore, the plasmid pK18mobsacB_Psod-carAB was constructed as follows: pK18mobsacB (Schaefer, 1994) was digested with EcoRI and HindIII, and the linearized vector DNA (5670 bps) was extracted from an agarose gel. DNA was extracted using the QIAquick PCR Purification Kit (Qiagen GmbH, Hilden, Germany).

[0126] For insert construction, three DNA fragments were generated by PCR using the following primer pairs (ATCC13032 genomic DNA as template): PsodcarAB-LA-F(SEQ ID NO:13)+PsodcarAB-LA-R(SEQ ID NO:14) = Left homology arm (1025 bps) PsodcarAB-F(SEQ ID NO:15)+PsodcarAB-R(SEQ ID NO:16) =sod-promoter(250bps) PsodcarAB-RA-F(SEQ ID NO:17)+PsodcarAB-RA-R(SEQ ID NO:18) = Right homology arm (944 bps) The product DNA was purified using a "QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany). The linearized plasmid and PCR product were then assembled using the "NEBuilder HiFi DNA Assembly Cloning Kit" (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520). Appropriate plasmid clones were identified by restriction digestion and DNA sequencing.

[0127] The resulting plasmid, pK18mobsacB_Psod-carAB, was then transformed into ATCC 13032 by electroporation. Chromosomal integration (resulting from the first recombination event) was selected by plating on BHI agar supplemented with 134 g / L sorbitol, 2.5 g / L yeast extract, and 25 mg / L kanamycin. Agar plates were incubated at 33°C for 48 h.

[0128] Individual colonies were transferred to fresh agar plates (containing 25 mg / L kanamycin) and incubated at 33°C for 24 hours. Liquid cultures of these clones were grown in 10 ml of BHI medium in three baffled 100 ml Erlenmeyer flasks at 33°C for 24 hours. To isolate clones that had undergone a second recombination event, aliquots were taken from each liquid culture, appropriately diluted, and plated (usually 100–200 μl) on BHI agar supplemented with 10% sucrose. These agar plates were incubated at 33°C for 48 hours. Colonies growing on the sucrose-containing agar plates were then tested for kanamycin sensitivity. To do this, cellular material was removed from the colonies using a toothpick and transferred to BHI agar plates containing 25 mg / L kanamycin and 10% sucrose. The agar plates were incubated at 33°C for 60 hours. Clones sensitive to kanamycin and resistant to sucrose were examined for proper integration of the sod promoter by PCR and DNA sequencing, and the resulting strain was designated ATCC13032_Psod-carAB.

[0129] Example 8: Chromosomal deletion of the gene aceB (NCgl2247) in C. glutamicum ATCC13032 To reduce the metabolic flux from glyoxylate to L-malate, the gene aceB (NCgl2247), encoding malate synthase (EC 2.3.3.9), was deleted in strain ATCC13032.

[0130] Therefore, the plasmid pK18mobsacB_DaceB was constructed as follows: The plasmid pK18mobsacB (Schaefer, 1994) was cleaved with XbaI, and the linearized vector DNA (5721 bps) was purified using a "QIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany).

[0131] For the construction of the insert, two DNA fragments were generated by PCR using the following primer pairs (ATCC13032 genomic DNA as a template): 1f-aceB-D2_vec(SEQ ID NO:19)+1r-aceB-D2_aceB(SEQ ID NO:20) = Left homology arm (1065 bps) 2f-aceB-D2_aceB(SEQ ID NO:21)+2r-aceB_D2_Vec(SEQ ID NO:22) = Left homology arm (1080bps) Product DNA was purified using the "QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).

[0132] The linearized plasmid and PCR product were then assembled using the "NEBuilder HiFi DNA Assembly Cloning Kit" (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520). The resulting deletion vector was designated pK18mobsacB_DaceB and was confirmed by restriction enzyme digestion and DNA sequencing.

[0133] To delete the aceB gene, pK18mobsacB_DaceB was transformed into ATCC13032 by electroporation. Chromosomal integration (resulting from the first recombination event) was selected by plating on BHI agar medium supplemented with 134 g / L sorbitol, 2.5 g / L yeast extract, and 25 mg / L kanamycin. Agar plates were incubated at 33°C for 48 hours.

[0134] Individual colonies were transferred to fresh agar plates (containing 25 mg / L kanamycin) and incubated at 33°C for 24 hours. Liquid cultures of these clones were grown in 10 ml of BHI medium in three baffled 100 ml Erlenmeyer flasks at 33°C for 24 hours. To isolate clones that had undergone a second recombination event, aliquots were taken from each liquid culture, appropriately diluted, and plated (usually 100–200 μl) on BHI agar supplemented with 10% sucrose. These agar plates were incubated at 33°C for 48 hours. Colonies growing on the sucrose-containing agar plates were then tested for kanamycin sensitivity. To do this, cellular material was removed from the colonies using a toothpick and transferred to BHI agar plates containing 25 mg / L kanamycin and 10% sucrose. The agar plates were incubated at 33°C for 60 hours. Clones sensitive to kanamycin and resistant to sucrose were examined by PCR and DNA sequencing for proper integration of the sod promoter, and the resulting strain was designated ATCC13032_DaceB.

[0135] Example 9: Chromosomal deletion of the gene aceB (NCgl2247) in C. glutamicum ATCC13032_Psod-carAB To reduce the metabolic flux from glyoxylate to L-malate, the gene aceB (NCgl2247), encoding malate synthase (EC 2.3.3.9), was deleted in the ATCC13032_Psod-carAB strain.

[0136] To delete the aceB gene, pK18mobsacB_DaceB was transformed into ATCC13032_Psod-carAB by electroporation. Chromosomal integration (resulting from the first recombination event) was selected by plating on BHI agar medium supplemented with 134 g / L sorbitol, 2.5 g / L yeast extract, and 25 mg / L kanamycin. Agar plates were incubated at 33°C for 48 hours.

[0137] Individual colonies were transferred to fresh agar plates (containing 25 mg / L kanamycin) and incubated at 33°C for 24 hours. Liquid cultures of these clones were grown in 10 ml of BHI medium in three baffled 100 ml Erlenmeyer flasks at 33°C for 24 hours. To isolate clones that had undergone a second recombination event, aliquots were taken from each liquid culture, appropriately diluted, and plated (usually 100–200 μl) on BHI agar plates supplemented with 10% sucrose. These agar plates were incubated at 33°C for 48 hours. Colonies growing on the sucrose-containing agar plates were then tested for kanamycin sensitivity. To do this, cellular material was removed from the colonies using a toothpick and transferred to BHI agar plates containing 25 mg / L kanamycin and 10% sucrose. The agar plates were incubated at 33°C for 60 hours. Clones sensitive to kanamycin and resistant to sucrose were examined for proper integration of the sod promoter by PCR and DNA sequencing, and the resulting strain was designated ATCC13032_Psod-carAB_DaceB.

[0138] [Table 9]

[0139] Example 10: Transformation of C. glutamicum strains with various expression plasmids The following strains of C. glutamicum were transformed with the plasmids by electroporation (Table 10). Plasmid-containing cells were selected with 25 mg / l kanamycin.

[0140] C. glutamicum ATCC13032: A commonly used wild-type strain (Kinoshita et al., J. Gen. Appl. Microbiol. 1957; 3(3): 193-205) C. glutamicum ATCC13032_DaceB: Decreased malate synthase activity due to chromosomal deletion of the aceB gene in ATCC13032 C. glutamicum ATCC13032_Psod-carAB_DaceB: Decreased malate synthase activity due to chromosomal deletion of the aceB gene in ATCC13032 and improved L-arginine production by chromosomal integration of the strong sod promoter upstream of carAB.

[0141] [Table 10]

[0142] Example 11: Effect of reduced malate synthase activity on GAA production To evaluate the effect of reduced malate synthase activity on GAA production, strains ATCC13032 / pEC-XK99E, ATCC13032 / pEC-XK99E_AGAT_Mp, and ATCC13032_DaceB / pEC-XK99E_AGAT_Mp were cultured in a Wouter Duetz system and the resulting GAA titers were measured. The production medium (PM) contained 40 g / L D-glucose and 1.90 g / L L-arginine, but no glycine was added.

[0143] [Table 11]

[0144] As shown in Table 11, the ATCC13032 / pEC-XK99E strain did not produce detectable amounts of GAA.

[0145] The ATCC13032 / pEC-XK99E_AGAT_Mp strain, which contained a polynucleotide encoding AGAT from Moorea producens, produced 122 mg / L of GAA.

[0146] The ATCC13032_DaceB / pEC-XK99E_AGAT_Mp strain, which contained a polynucleotide encoding AGAT from Moorea producens and a deleted aceB gene, produced 155 mg / L of GAA.

[0147] We conclude that, in the presence of AGAT enzyme activity, reducing the enzyme activity of malate synthase improves GAA production.

[0148] Example 12: Effect of a combination of decreased malate synthase activity and increased glyoxylate aminotransferase activity on GAA production To evaluate the effect of the combination of decreased malate synthase activity and increased glyoxylate aminotransferase activity on GAA production, strains ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGGT1, ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGGT2, and ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AGT_Tl were cultured in a Wouter-Dütz system and the resulting GAA titers were measured. The production medium (PM) contained 40 g / L D-glucose and 1.90 g / L L-arginine, but no additional glycine.

[0149] [Table 12]

[0150] As shown in Table 12, ATCC13032_DaceB / pEC-XK99E_AGAT_Mp, which has a polynucleotide encoding AGAT from Moorea producens and a deleted aceB gene, produced 155 mg / L of GAA.

[0151] Strains ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGGT1, ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGGT2, and ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AGT_Tl also contain a polynucleotide encoding AGAT from Moorea producens and a deleted aceB gene. Additionally, each strain contains a polynucleotide encoding glyoxylate aminotransferase. These strains produced 236 mg / L, 242 mg / L, and 180 mg / L of GAA, respectively.

[0152] We conclude that in the presence of AGAT enzyme activity, the combination of decreased malate synthase activity and increased glyoxylate aminotransferase activity improves GAA production.

[0153] Example 13: Effect of the combination of decreased malate synthase activity and increased L-arginine production capacity on GAA production To evaluate the effect of reduced malate synthase activity and enhanced L-arginine production on GAA production, strains ATCC13032_DaceB / pEC-XK99E_AGAT_Mp and ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp were cultured in a Wouter-Dütz system, and the resulting GAA titers were measured. The latter strain possesses enhanced L-arginine production due to the insertion of a strong sod promoter upstream of the chromosomal carA and carB genes. The production medium (PM) contained 40 g / L D-glucose and 1.90 g / L L-arginine, but no glycine was added.

[0154] [Table 13]

[0155] As shown in Table 13, ATCC13032_DaceB / pEC-XK99E_AGAT_Mp, which has a polynucleotide encoding AGAT from Moorea producens and a deleted aceB gene, produced 155 mg / L of GAA.

[0156] The ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp strain also contains a polynucleotide encoding AGAT from Moorea producens and a deleted aceB gene. Furthermore, it also has improved L-arginine production. This strain produced 243 mg / L of GAA.

[0157] We conclude that in the presence of AGAT enzyme activity, the combination of reduced malate synthase activity and improved L-arginine production capacity leads to improved GAA production.

[0158] Example 14: Combined effects of decreased malate synthase activity, increased glyoxylate aminotransferase activity, and improved L-arginine production capacity on GAA production To evaluate the combined effects of decreased malate synthase activity, increased glyoxylate aminotransferase activity, and improved L-arginine production on GAA production, strains ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGGT1, ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGGT2, and ATCC13032_DaceB / pEC-XK Strains 99E_AGAT_Mp_AGT_Tl, ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp_AtGGT1, ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp_AtGGT2, and ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp_AGT_Tl were cultured in a Wouter Duetz system, and the resulting GAA titers were measured. The latter three strains possess enhanced L-arginine production capabilities due to the insertion of a strong sod promoter upstream of the chromosomal carA and carB genes. The production medium (PM) contained 40 g / L D-glucose and 1.90 g / L L-arginine, but no glycine was added.

[0159] [Table 14]

[0160] As shown in Table 14, the ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGT1, ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_AtGT2, and ATCC13032_DaceB / pEC-XK99E_AGAT_Mp_Agt_Tl strains, which contained a polynucleotide encoding AGAT from Moorea producens, a deleted aceB gene, and a polynucleotide encoding glyoxylate aminotransferase, produced 236 mg / L, 242 mg / L, and 180 mg / L of GAA, respectively.

[0161] Strains ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp_AtGGT1, ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp_AtGGT2, and ATCC13032_Psod-carAB_DaceB / pEC-XK99E_AGAT_Mp_AGT_Tl also contain a polynucleotide encoding AGAT from Moorea producens, a deleted aceB gene, and a polynucleotide encoding glyoxylate aminotransferase. Furthermore, they have improved L-arginine production. These strains produced 362 mg / L, 354 mg / L, and 331 mg / L of GAA, respectively.

[0162] We conclude that the combination of decreased AGAT enzyme activity, decreased malate synthase activity, increased glyoxylate aminotransferase activity, and improved L-arginine production capacity leads to improved GAA production.

Claims

1. 1. A microorganism comprising at least one gene encoding a protein having the function of L-arginine:glycine amidinotransferase, wherein the activity of the protein having the function of malate synthase is reduced compared to the respective activity in a wild-type microorganism, said microorganism being Corynebacterium glutamicum, said microorganism having an improved ability to produce L-arginine compared to the ability of a wild-type microorganism, and said protein having the function of L-arginine:glycine amidinotransferase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence according to SEQ ID NO:

11.

2. The microorganism described in claim 1, wherein the expression of a gene encoding a protein having the function of malate synthase is attenuated compared to the expression of each gene in a wild-type microorganism, or the gene encoding a protein having the function of malate synthase is deleted.

3. 3. The microorganism according to claim 1, wherein the microorganism has an activity of an enzyme having the function of carbamoyl phosphate synthase, and the activity is increased compared to the respective enzymatic activity in a wild-type microorganism.

4. A microorganism according to claims 1 to 3, wherein the microorganism further comprises an enzyme having the function of ornithine carbamoyltransferase, the activity of which is increased compared to the respective enzymatic activity in a wild-type microorganism.

5. A microorganism described in any one of claims 1 to 4, wherein the microorganism further contains an enzyme having the function of argininosuccinate synthetase, the activity of which is increased compared to the respective enzymatic activity in a wild-type microorganism.

6. 6. A microorganism according to any one of claims 1 to 5, wherein the increased activity of the enzymes is achieved by overexpressing the genes encoding the respective enzymes.

7. 7. The microorganism of claim 1, wherein the arginine operon (argCJBDFR) is overexpressed.

8. The microorganism according to any one of claims 1 to 6, wherein expression of the argR gene encoding the arginine-responsive repressor protein ArgR is attenuated compared to expression of the argR gene in a wild-type microorganism, or the argR gene is deleted.

9. 9. The microorganism according to claim 1, wherein at least one or more genes encoding enzymes in the L-arginine biosynthetic pathway, including gdh, argJ, argB, argC, and / or argD, which encode glutamate dehydrogenase, ornithine acetyltransferase, acetylglutamate kinase, acetylglutamylphosphate reductase, and acetylornithine aminotransferase, respectively, are overexpressed.

10. 10. The microorganism according to claim 1, wherein the gene encoding a protein having the function of L-arginine:glycine amidinotransferase is heterologous.

11. The microorganism according to any one of claims 1 to 10, wherein the gene encoding the protein having the function of L-arginine:glycine amidinotransferase is overexpressed.

12. 12. A method for the fermentative production of guanidinoacetic acid (GAA), comprising the steps of: a) culturing a microorganism according to any one of claims 1 to 11 in a suitable medium under suitable conditions; and b) accumulating GAA in the medium to produce a GAA-containing fermentation broth.

13. 13. The method of claim 12, further comprising isolating GAA from the GAA-containing fermentation broth.

14. 14. The method of claim 12 or 13, further comprising drying and / or granulating the GAA-containing fermentation broth.

15. 12. The microorganism according to claim 1, further comprising a gene encoding an enzyme having guanidinoacetate N-methyltransferase activity.

16. The microorganism according to claim 15, wherein the gene encoding the enzyme having the activity of guanidinoacetate-N-methyltransferase is overexpressed.

17. 17. A method for the fermentative production of creatine, comprising the steps of: a) culturing a microorganism according to claim 15 or 16 in a suitable medium under suitable conditions; and b) accumulating creatine in the medium to produce a creatine-containing fermentation broth.

18. 20. The method of claim 17, further comprising isolating creatine from the creatine-containing fermentation broth.

Images